



7 April 2008

Dear Healthcare Professional:

ImaRx Therapeutics, Inc. would like to take this opportunity to thank you for your continued support of Abbokinase®. We would also like to share some important news with you. **ImaRx Therapeutics, Inc. has received approval from the FDA to change the brand name of Abbokinase (urokinase) to Kinlytic™ (urokinase for injection).**

**Please note that this is a change in name only.** There is:

- No change in active or inactive ingredients
- No change in formulation
- No change in indications
- No change in mechanism of action
- No change in preparation or dosing

Kinlytic (urokinase for injection) was originally approved for marketing as Abbokinase in 1978 and over 4 million patients have been treated to date. Kinlytic is a thrombolytic agent obtained from human neonatal kidney cells grown in tissue culture and is currently approved for the following indications in adults:

- Lysis of acute massive pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments.
- Lysis of pulmonary emboli accompanied by unstable hemodynamics, ie, failure to maintain blood pressure without supportive measures.

ImaRx has initiated programs to educate the medical community of the brand name change to Kinlytic, including physicians, pharmacists, allied healthcare professionals, wholesalers and group purchasing organizations. ImaRx anticipates availability of Kinlytic in hospital pharmacies in June 2008.

ImaRx Therapeutics, Inc., [www.imarx.com](http://www.imarx.com) is a biopharmaceutical company headquartered in Tucson, Arizona. We have entered into agreements with all of the major wholesalers and group purchasing organizations to provide an uninterrupted supply of Kinlytic to our customers. We will be serving our hospital customers through a direct sales force and providing customer support through our Tucson, Arizona headquarters. For additional questions or medical information please contact our customer support team at 1-866-63-ImaRx (866-634-6279).

We look forward to working with you and your hospital to help meet your patients' needs with Kinlytic.

Kind Regards,

A handwritten signature in black ink, appearing to read 'Garen Manvelian', is written over a white background.

Garen Manvelian, MD  
Chief Medical Officer

# ANNOUNCING

Nothing new but the name (and the NDC).



After 3 decades, the record speaks for itself.

**Urokinase is coming soon to your hospital as Kinlytic™.**  
**New NDC: 24430-1003-1**

Wholesalers may still have Abbokinase®-labeled inventory remaining in stock. ImaRx Therapeutics has instructed wholesalers to first deplete any Abbokinase-labeled inventory, and then make Kinlytic available to hospitals. **The Abbokinase NDC number is 24430-1001-01.**



KINLYTIC™  
UROKINASE FOR INJECTION



Urokinase is coming soon to your hospital as Kinlytic™ (urokinase for injection).

## How to order

Please contact your local wholesaler to order.

New NDC	Description	Pack Size	Case Size
24430-1003-1	Kinlytic (urokinase for injection) 250,000 international units 5-mL vial	Individual vials	24 vials per case

Wholesalers	Item/Product Number
AmerisourceBergen	771-985/5035449
Cardinal	4037271
McKesson	1791821
Morris & Dickson Co., LLC	827022
HD Smith	2123529

For medical information or to have a Kinlytic representative contact you,  
please call 866-63-ImaRx (866-634-6279) or go to [www.ImaRx.com](http://www.ImaRx.com)

Please see accompanying full Prescribing Information.

©2008 ImaRx Therapeutics, Inc. Kinlytic™ is a trademark of ImaRx Therapeutics, Inc.  
D08-004 02/08

**KINLYTIC™**  
UROKINASE FOR INJECTION

